These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 26628458)

  • 41. HIV preexposure prophylaxis in the real world.
    Daskalakis DC
    Top Antivir Med; 2014; 22(4):670-5. PubMed ID: 25398067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Editorial Commentary: Scaling Up Antiretroviral Preexposure Prophylaxis: Moving From Trials to Implementation.
    Mayer KH; Krakower DS
    Clin Infect Dis; 2015 Nov; 61(10):1598-600. PubMed ID: 26270688
    [No Abstract]   [Full Text] [Related]  

  • 44. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
    Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
    Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reaching High-Risk Patients for HIV Preexposure Prophylaxis.
    Riddell J; Cohn JA
    JAMA; 2016 Jul; 316(2):211-2. PubMed ID: 27404188
    [No Abstract]   [Full Text] [Related]  

  • 46. PrEP: A case study.
    Rowniak S
    J Am Assoc Nurse Pract; 2015 Jun; 27(6):296-9. PubMed ID: 25739647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
    Velloza J; Heffron R
    Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Science, technology, power and sex: PrEP and HIV-positive gay men in Paris.
    Brisson J; Nguyen VK
    Cult Health Sex; 2017 Oct; 19(10):1066-1077. PubMed ID: 28276922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emtricitabine/tenofovir alafenamide (Descovy) for HIV.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):100-1. PubMed ID: 27466750
    [No Abstract]   [Full Text] [Related]  

  • 50. PrEP as Peri-conception HIV Prevention for Women and Men.
    Heffron R; Pintye J; Matthews LT; Weber S; Mugo N
    Curr HIV/AIDS Rep; 2016 Jun; 13(3):131-9. PubMed ID: 26993627
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
    Mugwanya KK; John-Stewart G; Baeten J
    Expert Opin Drug Saf; 2017 Jul; 16(7):867-871. PubMed ID: 28571500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
    HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis.
    Holt M
    Cult Health Sex; 2015; 17(4):428-39. PubMed ID: 25270549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PrEP, Truvada, and Gilead.
    Jack A
    BMJ; 2016 Sep; 354():i4800. PubMed ID: 27609216
    [No Abstract]   [Full Text] [Related]  

  • 56. How to "PrEP" for HIV Prevention in Women.
    Ntim GJ; Kransdorf LN
    J Womens Health (Larchmt); 2017 Feb; 26(2):195-196. PubMed ID: 28140756
    [No Abstract]   [Full Text] [Related]  

  • 57. HIV preexposure prophylaxis for adolescents and young adults.
    Allen E; Gordon A; Krakower D; Hsu K
    Curr Opin Pediatr; 2017 Aug; 29(4):399-406. PubMed ID: 28598901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective.
    Conniff J; Evensen A
    J Am Board Fam Med; 2016; 29(1):143-51. PubMed ID: 26769887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
    Lorente N; Fugon L; Carrieri MP; Andreo C; Le Gall JM; Cook E; Aboulker JP; Capitant C; Molina JM; Spire B
    AIDS Care; 2012; 24(4):468-77. PubMed ID: 22085083
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.